- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01702688
Evaluation of Lysine-Specific Demethylase 1
Evaluation of Lysine-Specific Demethylase 1 As An Epigenetic Regulator of Salt Sensitive Hypertension
Thank you for your interest in our Blood Pressure Research Study. The American Heart Association is sponsoring us to investigate why patients develop high blood pressure, atherosclerosis (hardening of the arteries), and heart disease. There are two parts of our research program. The first part is a screening visit. At this visit you will be given a brief physical exam and will be asked questions concerning your medical history. During the same visit you will have your blood drawn for routine screening and genetic testing. You will also be asked to collect a urine sample for routine screening.
If the doctor finds that you are a healthy candidate you will be invited to participate in the second part of the study. During Phase II, we will perform physiological tests after you are placed on a low salt diet and again after you are placed on a higher salt diet. If you are on blood pressure medication, it may be necessary to discontinue taking your present medication for up to three months before beginning the study. Patients discontinuing their current blood pressure medication may be placed on a different blood pressure medication during this 'washout' period if necessary to maintain blood pressure at pre-study levels.
Once your blood pressure medications are discontinued, you will be closely monitored. If you do not own a home blood pressure monitor, we will provide one for you to use during the study so that you can keep a daily record of your blood pressure readings. We will ask you to call us every three days to report your blood pressure readings. After you have stopped taking your medication, dietitians at the hospital will make you low salt meals to eat at home for about seven days. On the last day of the low salt diet, you will be asked to begin a 24-hour urine collection that you will bring with you when you are admitted to the hospital that evening. That morning, you will be required to come to the Center for Clinical Investigations (CCI) at Brigham and Women's Hospital for a one-hour test to check if your body is in the correct salt balance.
You will return that evening to the CCI where you will be admitted for your study that will occur the next morning. On the morning of your low salt study, we will collect some blood samples. We will also take ultrasound pictures of your heart to see how salt and hormones affect the way your heart and blood vessels functions. These tests will last approximately 5 hours and you will be discharged around 2:00 PM. For the next 5-7 days, you will be placed on a liberal salt diet. During this diet period, you will eat all your own food, but we will give you some supplements to add to your meals. After 5-7 days on your liberal salt diet, on the morning of your second admission to the hospital, you will be asked to begin a final 24-hour urine collection. That morning, you will again be required to come to the CCI for a blood test, and you will return later that evening to the inpatient CCI where you will be admitted for your final overnight study. The same study that was done for the low salt diet will be repeated for the liberal salt study. You will be discharged at around 2:00 p.m. These studies will help to determine if you are salt-sensitive. In addition, we hope to learn more about the hormones that regulate your blood pressure and the genes responsible for regulating those hormones.
You will be placed back on your initial blood pressure medication (if you are on any) and returned to your regular physician for care. We can also provide clinically relevant information to you.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18-65
- mild to moderate hypertension
- no other major illnesses
- BMI < or equal to 40
Exclusion Criteria:
- secondary illnesses
- BMI > 40
- taking 4 or more anti-hypertensive medications
- BP >160/100 on screening exam
- Alcohol intake >12 oz per week
- Current smoking
- Recreational drug use
- use of birth control pills or contraceptive hormone shots
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluating for the mechanisms by which genetic variants in the LSD1 gene contribute to salt-sensitive hypertension and cardiovascular disease
Time Frame: 5 years
|
The overall goal of this study is to expand on our preliminary findings by further evaluating in human subjects with hypertension, the mechanisms underlying the interactions between Lysine-Specific Demethylase 1 (LSD1), dietary sodium and salt-sensitivity.
One objective is to test the hypothesis that in humans, LSD1 status modifies cardiovascular responses to changes in sodium intake.
The effect of LSD1 genotype on vascular and cardiac function will be assessed by performing vascular (aortic compliance) and cardiac (diastolic relaxation and cardiac strain) studies on liberal and low sodium diets in 3 groups of hypertensive subjects.
Additionally, we will test if salt sensitivity associated with LSD1 is related to impaired renal vascular response to dietary sodium and alterations in renal sodium excretion.
This proposal will better define how LSD1 influences CV function and its interaction with sodium intake.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bindu Chamarthi, MD, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012 Lysine
- AHA 12CRP11690012 (Other Grant/Funding Number: American Heart Association)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Para-aminohippuric Acid
-
University of Colorado, DenverActive, not recruitingObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Complications | Type 2 Diabetes Mellitus | Pediatric Obesity | Diabetic Kidney Disease | Diabetic Nephropathies | Weight Loss | Bariatric Surgery Candidate | Adolescent Obesity | NephropathyUnited States
-
University of Colorado, DenverActive, not recruitingObesity | Type 2 Diabetes Mellitus | Adolescent Obesity | NephropathyUnited States
-
University of Colorado, DenverCompletedDiabetes Mellitus, Type 1 | Diabetic Nephropathies | Type 1 Diabetes Mellitus | Diabetes Mellitus Complication | Nephropathy | Autoimmune Diabetes | Juvenile DiabetesUnited States
-
Florida International UniversityUniversity of Southern California; Universidad Peruana Cayetano HerediaRecruitingHIV Infections | Sexually Transmitted Diseases | Hiv | Sexual Behavior | Risk Reduction | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
University of Colorado, DenverJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus | Diabetes | Diabetes Complications | Type1diabetes | Type 1 Diabetes | Diabetic Kidney Disease | Diabetic Nephropathies | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes, Autoimmune | Juvenile DiabetesUnited States
-
University of Colorado, DenverCompletedPolycystic Kidney, Autosomal Dominant | Polycystic Kidney Disease, AdultUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingType 2 Diabetes Mellitus | Diabetic Kidney Disease | Adolescent Obesity | Puberty | Pre Diabetes | Kidney HypoxiaUnited States
-
University of Colorado, DenverEnrolling by invitationObesity | Diabetic Kidney Disease | Diabetic Nephropathies | Type 2 Diabetes | Adolescent Obesity | Nephropathy | Diabetes Type 2United States
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Type 1 Diabetes | Diabetic Kidney Disease | Endothelial Dysfunction | Insulin SensitivityUnited States
-
Columbia UniversityNational Cancer Institute (NCI)Unknown